RZL-012 for Dercum's Disease Lipomas

Inclusion Criteria: * At least 4 painful lipomas of appropriate size to be injected on a background of Dercum's Disease. * Generally considered healthy according to medical history, physical examination, electrocardiogram (ECG) and laboratory evaluation with an emphasis on metabolic parameters (fasting glucose concentration \< 200 mg/dL). * Subjects must be able to adhere to the visit schedule and protocol requirements and be capable of completing the study. * Males or females in the age of fertility are willing to refrain from sexual activity or agree to use a double-barrier contraceptive device (e.g., condom and spermicide) for 4 weeks after treatment with RZL 012. * Subjects must sign an informed consent indicating they are aware of the investigational nature of the study. Exclusion Criteria: * Unable to tolerate subcutaneous injections. * Pregnant women. * Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that in the opinion of the investigator places the subject at significant risk. * Positive blood screen for Hepatitis B surface antigen (HbSAg), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV). * Subjects with a clinical history of active primary or secondary immunodeficiency, autoimmune disease or subjects taking immunosuppressive drugs such as corticosteroids * Subjects with dysfunctional gallbladder activity, e.g. underwent cholecystectomy or cholecystitis. * As a result of medical review and physical examination, the PI (or medically qualified nominee) considers the subject unfit for the study. * Known sensitivity to components of the injection formulation. * Prior wound, tattoo or infection in the treated area. * Prior invasive treatment such as surgery or injectable drug at the RZL-012 injected area. * Subjects treated chronically at least 3 months prior to study entry with systemic steroids or immunosuppressive drugs. * Subjects treated chronically at least one week prior to study entry with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). * Current participation or participation within 3 months prior to the start of this study in a drug or other investigational research study.